Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7658)	11/5/1998 3:06:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Has anybody heard of Vancomycin Resistance Enterococci?

To: Bluegreen who wrote (7658)	11/6/1998 10:50:00 AM
From: Slugger	Read Replies (2) \| Respond to of 17367

Can you give us a quick technical read? WHAT is going on here? Blue, I think it's called making money (unless, of course, you've been in XOMA since 1992).:-) Technically we've broken above the 200 day MA. Most techies consider the 200 day MA an indicator of a bull or a bear trend in a stock, if a stock is above the line it is bullish. There looks to be the potential for resistance in the 4 1/2 to 5 range, so we might see a much need pull back from that area. Of course, news from the FDA will make all technical indicators worthless in this stock. Slugger

To: Bluegreen who wrote (7658)	11/9/1998 7:36:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

Unfortunately we are not going to find out if it was short covering until Dec. RapidResearch shows 54 institutions holding 8.2% of stock (7/20 was 55 inst holding 8%), so heavy institutional buying is unlikely. One would have to ask the question, "Who would be willing to chase a stock by paying ever higher prices for it?" I feel the answer is the "retail investor." The run-up smacks of one or two investment services recommending the stock and their subscribers subsequently piling on, but I have not been able to locate any new 'buy' recommendations, perhaps someone else knows. Double test of the $2 area, held both times. Shows strong technical support at this level. Those who purchased in this area are now sitting on handsome profits, but I think it only logical for the market to analyze the current $4.50 - 5.25 area for awhile. If for no other reason than it represents a double from the recent lows. A double in this market is hard to pass up. If the stock has an additional strong day, and blows past $5.50, then I would reconsider the possibility of institutional buying based upon knowledge not readily available to, or free for, the general public.